DelveInsight’s “HR-positive/HER2-negative Breast Cancer Pipeline Insight” report provides comprehensive insights about key companies and pipeline drugs in the HR-positive/HER2-negative Breast Cancer pipeline landscapes. It comprises HR-positive/HER2-negative Breast Cancer pipeline drug profiles, including clinical and non-clinical stage products. It also includes the HR-positive/HER2-negative Breast Cancer therapeutics assessment by product type, stage, route of administration, and molecule type and further highlights the inactive HR-positive/HER2-negative Breast Cancer pipeline products.
Some of the key takeaways of the HR-positive/HER2-negative Breast Cancer Pipeline Report
Companies across the globe are diligently working toward the development of novel treatment therapies with a considerable amount of success over the years. Key players, such as Jiangsu HengRui Medicine, Radius Pharmaceuticals, Immunomedics, Roche, Syndax Pharmaceuticals, Merck Sharp and Dohme, Merck Sharp and Dohme Corp./Eisai, Bayer, etc., are developing therapies for the treatment of HR-positive/HER2-negative Breast Cancer.
Emerging therapies such as SHR6390, Elacestrant (RAD1901), Sacituzumab govitecan, Ipatasertib and Venclexta, Entinostat, Pembrolizumab, Eribulin Mesylate, Radium-223 dichloride, are expected to have a significant impact on the HR-positive/HER2-negative Breast Cancer market in the coming years.
The postmenopausal breast cancer market size within the 7MM was found to be USD 6,315.1 million in 2018.
The HR-positive/HER2-negative Breast Cancer market size shall increase during the forecast period 2021–2030.
Among the 7MM, the US accounts for 80.51% USD of the HR-positive/HER2-negative Breast Cancer market size in 2018.
Get an overview of pipeline landscape @HR-positive/HER2-negative Breast Cancer Clinical Trials Analysis
HR-positive/HER2-negative breast cancer is the commonest carcinoma and also accounts for a better percentage of all breast cancers. HR-positive cancer is typically treated with hormone therapies or a combination of hormone therapies with targeted therapy to assist stop tumor growth.
HR-positive/HER2-negative Breast Cancer Emerging Drugs
SHR6390 by Jiangsu HengRui Medicine
Elacestrant (RAD1901) by Radius Pharmaceuticals
Sacituzumab govitecan by Immunomedics
Ipatasertib and Venclexta by Roche
Entinostat by Syndax Pharmaceuticals
Pembrolizumab by Merck Sharp and Dohme
Eribulin Mesylate by Merck Sharp and Dohme Corp./Eisai
Radium-223 dichloride by Bayer
And others.
Scope of HR-positive/HER2-negative Breast Cancer Pipeline Drug Insight
Coverage: Global
Major Players: Jiangsu HengRui Medicine, Radius Pharmaceuticals, Immunomedics, Roche, Syndax Pharmaceuticals, Merck Sharp and Dohme, Merck Sharp and Dohme Corp./Eisai, Bayer, and others.
Pipeline Therapies: SHR6390, Elacestrant (RAD1901), Sacituzumab govitecan, Ipatasertib and Venclexta, Entinostat, Pembrolizumab, Eribulin Mesylate, Radium-223 dichloride, and others.
Table of Contents
1
HR-positive/HER2-negative Breast Cancer Report Introduction
2
HR-positive/HER2-negative Breast Cancer Executive Summary
3
HR-positive/HER2-negative Breast Cancer Overview
4
HR-positive/HER2-negative Breast Cancer- Analytical Perspective In-depth Commercial Assessment
5
HR-positive/HER2-negative Breast Cancer Pipeline Therapeutics
6
HR-positive/HER2-negative Breast Cancer Late Stage Products (Phase II/III)
7
HR-positive/HER2-negative Breast Cancer Mid Stage Products (Phase II)
8
HR-positive/HER2-negative Breast Cancer Early Stage Products (Phase I)
9
HR-positive/HER2-negative Breast Cancer Preclinical Stage Products
10
HR-positive/HER2-negative Breast Cancer Therapeutics Assessment
11
HR-positive/HER2-negative Breast Cancer Inactive Products
12
Company-University Collaborations (Licensing/Partnering) Analysis
13
HR-positive/HER2-negative Breast Cancer Key Companies
14
HR-positive/HER2-negative Breast Cancer Key Products
15
HR-positive/HER2-negative Breast Cancer Unmet Needs
16
HR-positive/HER2-negative Breast Cancer Market Drivers and Barriers
17
HR-positive/HER2-negative Breast Cancer Future Perspectives and Conclusion
18
HR-positive/HER2-negative Breast Cancer Analyst Views
19
Appendix
20
About DelveInsight
Get a customized pipeline report @HR-positive/HER2-negative Breast Cancer Drugs Pipeline Report
Media ContactCompany Name: DelveInsight Business Research LLPContact Person: Kritika RehaniEmail: Send EmailPhone: 9193216187Address:304 S. Jones Blvd #2432 City: Las VegasState: NevadaCountry: United StatesWebsite: https://www.delveinsight.com/